Previous 10 |
Omega Therapeutics to Present at the Chardan Virtual 5th Annual Genetic Medicines Conference PR Newswire CAMBRIDGE, Mass. , Sept. 27, 2021 /PRNewswire/ -- Omega Therapeutics, Inc. (Nasdaq: OMGA) ("Omega"), a development-stage biotechnology company pioneering...
Omega Therapeutics Reports Second Quarter 2021 Financial Results and Outlines Key Corporate Objectives - Strong Balance Sheet to Fund Pipeline of Omega Epigenomic Controllers™ with $122.4 Million in Cash and Cash Equivelents as of June 30, 2021 and additional $141.1 Milli...
You can read full article here. For further details see: Wall Street Breakfast: The Week Ahead (Podcast)
Listen on the go! A daily podcast of Wall Street Breakfast will be available by 8:00 a.m. on Seeking Alpha, iTunes, Stitcher and Spotify. Economic reports in the week ahead Market watchers will be locked in on the Federal Reserve Bank of Kansas City's annual Economic Policy Symposium as the h...
News, Short Squeeze, Breakout and More Instantly...
Omega Therapeutics Inc. Company Name:
OMGA Stock Symbol:
NASDAQ Market:
Omega Therapeutics Inc. Website:
CAMBRIDGE, Mass., June 24, 2024 (GLOBE NEWSWIRE) -- Omega Therapeutics, Inc. (Nasdaq: OMGA) (“Omega”), a clinical-stage biotechnology company pioneering the development of a new class of programmable epigenomic mRNA medicines, today announced the election of Richard N. Kender to its...
CAMBRIDGE, Mass., May 30, 2024 (GLOBE NEWSWIRE) -- Omega Therapeutics, Inc. (Nasdaq: OMGA) (“Omega”), a clinical-stage biotechnology company pioneering the development of a new class of programmable epigenomic mRNA medicines, today announced that management will participate in fires...
CAMBRIDGE, Mass., May 29, 2024 (GLOBE NEWSWIRE) -- Omega Therapeutics, Inc. (Nasdaq: OMGA) (“Omega”), a clinical-stage biotechnology company pioneering the development of a new class of programmable epigenomic mRNA medicines, today announced the appointment of Kaan Certel, Ph.D., as...